JP2015521041A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521041A5
JP2015521041A5 JP2015511948A JP2015511948A JP2015521041A5 JP 2015521041 A5 JP2015521041 A5 JP 2015521041A5 JP 2015511948 A JP2015511948 A JP 2015511948A JP 2015511948 A JP2015511948 A JP 2015511948A JP 2015521041 A5 JP2015521041 A5 JP 2015521041A5
Authority
JP
Japan
Prior art keywords
pkn3
inhibitor
vegfr1
suffering
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521041A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/001441 external-priority patent/WO2013170960A1/en
Publication of JP2015521041A publication Critical patent/JP2015521041A/ja
Publication of JP2015521041A5 publication Critical patent/JP2015521041A5/ja
Pending legal-status Critical Current

Links

JP2015511948A 2012-05-16 2013-05-15 Pkn3阻害剤投与のためのバイオマーカーとしてのvegfr1の使用 Pending JP2015521041A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12003888.0 2012-05-16
EP12003888 2012-05-16
PCT/EP2013/001441 WO2013170960A1 (en) 2012-05-16 2013-05-15 Use of vegfr1 as a biomarker for pkn3 inhibitor administration

Publications (2)

Publication Number Publication Date
JP2015521041A JP2015521041A (ja) 2015-07-27
JP2015521041A5 true JP2015521041A5 (https=) 2016-07-07

Family

ID=48446240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511948A Pending JP2015521041A (ja) 2012-05-16 2013-05-15 Pkn3阻害剤投与のためのバイオマーカーとしてのvegfr1の使用

Country Status (4)

Country Link
US (2) US9133515B2 (https=)
EP (1) EP2849771A1 (https=)
JP (1) JP2015521041A (https=)
WO (1) WO2013170960A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016083623A1 (en) * 2014-11-28 2016-06-02 Silence Therapeutics Gmbh Means for the treatment of pre-eclampsia
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US20040220128A1 (en) * 1995-10-26 2004-11-04 Sirna Therapeutics, Inc. Nucleic acid based modulation of female reproductive diseases and conditions
DE59708838D1 (de) 1996-08-30 2003-01-09 Jens Peter Fuerste Spiegelselektion und spiegelevolution von nucleinsäuren
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
PT1536827E (pt) 2002-08-14 2009-03-20 Silence Therapeutics Ag Utilização de proteína cinase n beta
KR101670085B1 (ko) 2006-07-21 2016-10-28 사일런스 테라퓨틱스 게엠베하 단백질 키나아제 3의 발현을 억제하기 위한 수단

Similar Documents

Publication Publication Date Title
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
CY1122796T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων
LT3321276T (lt) Sulieti baltymai, skirti metabolinių sutrikimų gydymui
JP2015503422A5 (https=)
EP2760371A4 (en) VENTRICULAR TRANSCATHETER RECONSTRUCTION STRUCTURES, METHODS AND SYSTEMS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE AND OTHER SUFFERING
LT2945642T (lt) Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
JP2015513557A5 (https=)
LT3206716T (lt) Kanabinoidų panaudojimas atoninių traukulių gydymui, esant lennox-gastaut' sindromui
PL3725810T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu złośliwego
HK1223795A1 (zh) 拉喹莫德响应性的基因表达生物标志物
IL231228A0 (en) Bicyclic heterocycle derivatives for the treatmen t of pulmonary arterial hypertension
HUE049323T2 (hu) Hízósejt-stabilizálók tüdõbetegség kezelésére
PT2989110T (pt) Derivados de tamoxifeno para o tratamento de doenças neoplásicas, especialmente com nível elevado de proteína her2
ZA201403549B (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
EA201500997A1 (ru) Терапевтические применения эмпаглифлозина
HUE045724T2 (hu) GRPR antagonisták GRPR-pozitív rák kimutatására, diagnózisára és kezelésére
WO2012112315A3 (en) Methods for diagnosis of kawasaki disease
EA201590359A1 (ru) Лечение ревматоидного артрита
CY2020015I1 (el) Σικλεσονιδη για τη θεραπεια της νοσου των αεραγωγων σε αλογα
HK1212713A1 (zh) Vegfr1抗體的治療性用途
HRP20181554T4 (hr) Tauroursodezoksikolna kiselina (tudca), namijenjena upotrebi u liječenju neurodegenerativnih poremećaja
HUE053229T2 (hu) FK506 alkalmazása pulmonális artériás hipertenzió kezelésére
HUE043419T2 (hu) Vegyületek remielinizációs blokk kezelésére HERV-W borítékfehérje expresszióval járó betegségekben
EP2956475A4 (en) MODIFIED INGAP PEPTIDES FOR THE TREATMENT OF DIABETES
LT2872145T (lt) Sujungti benzazepinai tureto sindromui gydyti